No deal bucko
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

PointsBet (ASX:PBH) has essentially rejected BlueBet’s Wednesday takeover offer of the company based on the fact the latter needs to raise $160M to pull it off and that benefits were based on ‘assumed synergies.’

In other words: they’ve told BlueBet to get real.

Complicating matters is that the company already faces a takeover offer from another company called MIXI. PointsBet and MIXI are both reportedly undertaking exclusivity arrangements.

While BlueBet’s offer could value PointsBet up to $1.09/sh, there are the aforementioned issues which make MIXI’s offer of $1.06/sh a more enticing deal.

Mainly, MIXI actually has the money.

“The Board determined that the [BlueBet] Proposal could not reasonably be expected to lead to a superior proposal to that announced earlier today from MIXI,” PointsBet wrote on Thursday.

“The [BlueBet] Proposal was unfunded, subject to an explicit financing condition, and would require BlueBet to both raise $100m in debt and undertake a large upfront capital raising.

PointsBet also took issue with BlueBet’s vague wording around ‘synergies’ – no details of what those synergies would actually be or look like were included in Wednesday’s offer.

PBH last traded at $1.12/sh.

Join the discussion: See what HotCopper users are saying about PointsBet and be part of the conversations that move the markets.

PBH by the numbers
More From The Market Online
Market concept

(Last) Market Close (of 2025): October back again as DRO, EOS & 4DX pop; otherwise mid day

If you wanted to feel like you were re-living the festivity season for the XJO that was October, look no further than today’s

EV Resources on ‘accelerated pathway’ to Los Lirios restart after strong antimony recovery tests

EV Resources is inching closer to a Los Lirios restart after strong metallurgical results set up…
Magneto scan concept

MRI scans changed medicine – what disruptive tech is next? Enter Compumedics, up +50% YoY

Compumedics, a biotech company developing its Orion Lifespan MEG product, could just be the next big…

Coles, Woolies left furious over gov’t checks designed to limit ‘excessive pricing on groceries’

Coles and Woolworths have come out swinging against the government's plan to impose stricter rules to…